After some early turbulence in 2020, psychedelic drug stocks have taken off.
After some early turbulence in 2020, psychedelic drug stocks have taken off.
Psychedelic stocks are hitting new highs -- and doing so on record trading volumes. Feeding frenzies.
The company is set to open a therapeutic health and training center in Kelowna, British Columbia in May of 2021
Leading psychedelic stocks have gone ballistic in recent weeks. But where will investors find the NEXT multi-bagger opportunity?
Mind Cure Health will be focusing its psychedelic drug R&D on psilocybin, ketamine and ibogaine. The Company will be pursuing both pain-based and mental health applications for psychedelics.
Mind Cure's initial R&D focus will be on psilocybin, ketamine and ibogaine. Researching both pain and mental health applications for psychedelics.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now